Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Songha® Night; Drug: Oxazepam; Drug: Placebo

• Registration Number: NCT02273453
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to determine the presence of a hang-over effect in healthy volunteers the day after the administration of Songha® Night

Detailed Description

Not available

Study Timeline

• Study Start: 2003-02
• Primary Completion: 2003-06
• Status Verified: 2014-10
• Study First Submitted: 2014-10-23
• Study First Submitted QC: 2014-10-23
• Last Update Submitted: 2014-10-23
• Study First Posted: 2014-10-24
• Last Update Posted: 2014-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• Healthy male or female Caucasian subjects aged 20-60 years
• Normal outcome in Pittsburgh Sleep Quality Index (PSQI), below mean +2 Standard Deviation (SDs)
• No manifest sleep disorder diagnosed by polysomnography
• Normal pupillary function
• Willing and able to give written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to participation in the study and able to perform the study during the full time period of 36 days

Exclusion Criteria

• Subjective sleep duration of less than 3 hours in the night before the test
• Caffeine, nicotine or alcohol on the day (from midnight) of the test
• Alcohol consumption on the evening before visits 3, 5 or 7
• Eye-drops or other drugs, taken orally or intravenously, influencing pupil size or motility
• Shift work
• Drug and alcohol abuse
• Use of psycho-active drugs during the past 30 days
• Any treatment that might interfere with the evaluation of the test drug
• Any drug known to interact with benzodiazepines and related drugs, e.g. antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450
• Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
• Known hypersensitivity to any of the ingredients of the study drugs
• Pregnant or nursing women or inadequate birth control methods (this applies to female of childbearing potential only)
• Participation in another trial within the past 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo + Oxazepam	Placebo	-
Placebo	Placebo	-
Songha® Night	Songha® Night	-
Placebo + Oxazepam	Oxazepam	-

Primary Outcome Measures

Name	Time	Method
Changes from baseline of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test	08:00h, 09:30h, 11:00h at Day 7 of each treament period

Secondary Outcome Measures

Name	Time	Method
Change in subjective sleepiness rated on a 7 point scale	up to day 36	Stanford Sleepiness Scale
Global Assessment of tolerability by investigator on 4-point scale	Day 36
Change of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test	up to day 36
Change in subjective sleepiness measured on a visual analogue scale (VAS)	up to day 36
Change in sleep quality measured on a visual analogue scale (VAS)	up to day 36
Global Assessment of tolerability by patient on 4-point scale	Day 36
Number of subjects with adverse events	up to 36 days